RNAZ Projected Dividend Yield
Com Par $0.0001/TransCode Therapeutics Inc ( NASDAQ : RNAZ )TransCode Therapeutics, Inc. is a clinical-stage oncology company focusing on metastatic disease treatment through RNA therapeutics using their TTX nanoparticle platform. Their lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a key biomarker. Their preclinical projects include TTX-siPDL1, which modulates PD-L1, TTX-RIGA, an RNA-based RIG-I agonist enhancing innate immunity in tumors, and TTX-CRISPR, a CRISPR/Cas9 therapy for correcting cancer genes. Additionally, they have TTX-mRNA, a platform for creating cancer vaccines specific to tumor types. 21 YEAR PERFORMANCE RESULTS |
RNAZ Dividend History Detail RNAZ Dividend News RNAZ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |